GSK at ERS
INTERNATIONAL CONGRESS 2019MADRID Spain, 28 Sept - 2 Oct
Visita GSK (G.02 e H.01) per scoprire le nostre evidenze scientifiche. Partecipa ai nostri 3 simposi e non mancare alle nostre discussioni quotidiane con gli esperti. Ti diamo il benvenuto per aiutarci a iniziare i nostri prossimi 50 anni di innovazione.
Non parteciperai all'ERS? Guarda i simposi e i nostri highlight giornalieri
PROGRAMMA DEGLI EVENTI
Dom 29 Sett
Simposio
Can a reduction in risk lead to an improvement in asthma control?
17:15 − 19:15
Respiratory Forum at GSK stand
12:45 − 14:45
Dom 29 Sett
Simposio
Can a reduction in risk lead to an improvement in asthma control?
17:15 − 19:15
N104
Key Speakers
Dr Luis Perez de Llano
Spain
Dr Dave Leather
GSK, UK
Prof Andrew Greening
UK
Prof Tari Haahtela
Finland
Prof Ashley Woodcock
UK
Prof Huib Kerstjens
Netherlands
Time
Can a reduction in risk lead to an improvement in asthma control?
Speakers
17:15 − 17:25
Chairman’s introduction
Dr. Luis Perez de Llano
Dr. David Leather
Dr. David Leather
17:25 − 17:45
Why at all stages of disease do we need to strive to gain asthma control
Prof. Andrew Greening
17:45 − 18:05
Learning from the past to advance and optimise care:
Don’t forget the things we have already learned
Don’t forget the things we have already learned
Prof. Tari Haahtela
18:05 − 18:25
Evidence of effectiveness in asthma
Prof. Ashley Woodcock
18:25 − 18:55
Why striving for effectiveness in maintenance therapy could lead to a reduction in risk
Prof. Huib Kerstjens
18:55 − 19:15
Q&A
Dr. Luis Perez de Llano
Dr. David Leather
Dr. David Leather
17:15 − 17:25
Dr. Luis Perez de Llano
Dr David Leather
Dr David Leather
Chairman’s introduction
17:25 − 17:45
Prof. Andrew Greening
Why at all stages of disease do we need to strive to gain asthma control
17:45 − 18:05
Prof. Tari Haahtela
Learning from the past to advance and optimise care: Don’t forget the things we have already learned
18:05 − 18:25
Prof. Ashley Woodcock
Evidence of effectiveness in asthma
18:25 − 18:55
Prof. Huib Kerstjens
Why striving for effectiveness in maintenance therapy could lead to a reduction in risk
18:55 − 19:15
Dr. Luis Perez de Llano
Dr David Leather
Dr David Leather
Q&A
Descrizione
Discuteremo sull'importanza di sviluppare farmaci nella vita reale - compreso l'uso di potenti molecole che forniscono un'efficacia comprovata e riducano problematiche sulla safety - così come i fattori che consentono un maggiore controllo dell'asma.
RESPIRATORY FORUMS
Discuti le principali aree di interesse con i medical expert di GSK, dal vivo nel nostro stand commerciale
Discussion Themes
Time
Speakers
A treatable traits approach to management of the symptomatic breathless patient: learnings from the recent EMAX trial
12:45 − 13:15
TBC
Nucala▼ (Mepolizumab) : The long-term efficacy evidence supporting clinician’s choice
13:30 − 14:00
TBC
A treatable traits approach to managing the patient at risk of exacerbations: the latest data from the IMPACT trial
14:15 − 14:45
TBC
12:45 − 13:15
TBC
A treatable traits approach to management of the symptomatic breathless patient: learnings from the recent EMAX trial
13:30 − 14:00
TBC
Nucala▼ (Mepolizumab) : The long-term efficacy evidence supporting clinician’s choice
14:15 − 14:45
TBC
A treatable traits approach to managing the patient at risk of exacerbations: the latest data from the IMPACT trial
Lun 30 Sett
Simposio
Are we doing too little too late in COPD management?
17:15 − 19:15
Respiratory Forum at GSK stand
12:45 − 14:45
Lun 30 Sett
Simposio
Are we doing too little too late in COPD management?
17:15 − 19:15
Room 6F
Key Speakers
Prof Alvar Agusti
Spain
Prof Paul Jones
GSK, UK
Prof David Newby
UK
Prof François Maltais
Canada
Prof Mark Dransfield
USA
Prof Neil Barnes
GSK, UK
Time
Are we doing too little too late in COPD management?
Speakers
17:15 − 17:25
Co-Chair’s introduction
Prof. Alvar Agusti
Co-Chair
Co-Chair
17:25 − 17:40
Are others doing better: Can we learn from cardiologists?
Prof. David Newby
17:40 − 18:00
Can we more effectively manage COPD symptoms?
Prof. François Maltais
18:00 − 18:10
Q&A
Led by Prof. Paul Jones
and Prof. Alvar Agusti
and Prof. Alvar Agusti
18:10 − 18:35
Can we better manage the risk of future COPD exacerbations?
Prof. Mark Dransfield
18:35 − 18:55
Why early optimisation of the treatment of COPD matters
Prof. Neil Barnes
18:55 − 19:00
Drawing it all together: Call to Action
Prof. Paul Jones
19:00 − 19:15
Q&A
Led by Prof. Paul Jones
and Prof. Alvar Agusti
and Prof. Alvar Agusti
17:15 − 17:25
Prof. Alvar Agusti
Co-Chair
Co-Chair
Co-Chair’s introduction
17:25 − 17:40
Prof. David Newby
Are others doing better: Can we learn from cardiologists?
17:40 − 18:00
Prof. François Maltais
Can we more effectively manage COPD symptoms?
18:00 − 18:10
Led by Prof. Paul Jones and
Prof. Alvar Agusti
Prof. Alvar Agusti
Q&A
18:10 − 18:35
Prof. Mark Dransfield
Can we better manage the risk of future COPD exacerbations?
18:35 − 18:55
Prof. Neil Barnes
Why early optimisation of the treatment of COPD matters
18:55 − 19:00
Prof. Paul Jones
Drawing it all together: Call to Action
19:00 − 19:15
Led by Prof. Paul Jones and
Prof. Alvar Agusti
Prof. Alvar Agusti
Q&A
DESCRIZIONE
Affronteremo il rischio delle strategie di management per la gestione della BPCO nei pazienti con patologie cardiovascolari. Discuteremo come massimizzare la gestione del sintomo e prevenire il rischio futuro di esacerbazioni. Discuteremo inoltre dell'importanza di iniziare precocemente il trattamento.
RESPIRATORY FORUMS
Discuti le principali aree di interesse con i medical expert di GSK, dal vivo nel nostro stand commerciale.
Discussion Themes
Time
Speakers
A treatable traits approach to management of the symptomatic breathless patient: learnings from the recent EMAX trial
12:45 − 13:15
TBC
A treatable traits approach to managing the patient at risk of exacerbations: the latest data from the IMPACT trial
13:30 − 14:00
TBC
Nucala : ‘Power to Choose’: What does it mean for SEA patients?
14:15 − 14:45
TBC
12:45 − 13:15
TBC
A treatable traits approach to management of the symptomatic breathless patient: learnings from the recent EMAX trial
13:30 − 14:00
TBC
A treatable traits approach to managing the patient at risk of exacerbations: the latest data from the IMPACT trial
14:15 − 14:45
TBC
Nucala : ‘Power to Choose’: What does it mean for SEA patients?
Mart 1 Ott
Simposio
Mepolizumab▼ completing the story: Eosinophils, real-world evidence and the power to choose
17:15 − 19:15
Respiratory Forum at GSK stand
12:45 − 14:45
Mart 1 Ott
Simposio
Mepolizumab▼ completing the story: Eosinophils, real-world evidence and the power to choose
17:15 − 19:15
N104
Key Speakers
Dr Santiago Quirce
Spain
Prof Neil Barnes
GSK, UK
Dr Stephanie Korn
Germany
Prof William Busse
USA
Prof Ian Pavord
UK
Time
Session Title
Speakers
17:15 − 17:25
Chair’s introduction
Dr. Santiago Quirce
17:25 − 17:45
Long-term evidence: A clinician’s perspective
Dr. Stephanie Korn
17:45 − 18:05
Discussion: Eosinophils in health and disease
Moderator: Prof. Neil Barnes
Dr. Peter Howarth (GSK)
and Prof. Ian Pavord (UK)
Dr. Peter Howarth (GSK)
and Prof. Ian Pavord (UK)
18:05 − 18:25
At-home administration: A positive choice for patients
Prof. Ian D. Pavord
18:25 − 18:55
Mepolizumab: A new reality for clinicians
Prof. William Busse
18:55 − 19:15
Q&A
Led by Dr. Santiago Quirce
and Prof. Neil Barnes
and Prof. Neil Barnes
17:15 − 17:25
Dr. Santiago Quirce
Chair’s introduction
17:25 − 17:45
Dr. Stephanie Korn
Long-term evidence: A clinician’s perspective
17:45 − 18:05
Moderator: Prof. Neil Barnes
Dr. Peter Howarth (GSK)
and Prof. Ian Pavord (UK)
Dr. Peter Howarth (GSK)
and Prof. Ian Pavord (UK)
Discussion: Eosinophils in health and disease
18:05 − 18:25
Prof. Ian D. Pavord
At-home administration: A positive choice for patients
18:25 − 18:55
Prof. William Busse
Mepolizumab: A new reality for clinicians
18:55 − 19:15
Led by Dr. Santiago Quirce
and Prof. Neil Barnes
and Prof. Neil Barnes
Q&A
DESCRIZIONE
Sarà presentata una overview delle evidenze a lungo termine che supportano l'efficacia clinica e il profilo di safety di Mepolizumab nei pazienti con asma eosinofilo refrattaria. Esamineremo inoltre il profilo dei pazienti che maggiormente possono beneficiare della terapia, considerando la complessità delle nuove opzioni di trattamento con biologici nei sottotipi di asma severa.
Respiratory Forums
Discuti le principali aree di interesse con i medical expert di GSK, dal vivo nel nostro stand commerciale
Discussion Themes
Time
Speakers
Nucala : The long-term efficacy evidence supporting clinician’s choice
12:45 − 13:15
TBC
Fluticasone furoate: a modern inhaled steroid
13:30 − 14:00
TBC
Nucala : ‘Power to Choose’: What does it mean for SEA patients?
14:15 − 14:45
TBC
12:45 − 13:15
TBC
Nucala : The long-term efficacy evidence supporting clinician’s choice
13:30 − 14:00
TBC
Fluticasone furoate: a modern inhaled steroid
14:15 − 14:45
TBC
Nucala : ‘Power to Choose’: What does it mean for SEA patients?
VISITA IL NOSTRO STAND
Guarda come il nostro approccio alla medicina respiratoria ha continuato a migliorare ovunque le vite dei pazienti
STAND COMMERCIALE
STAND COMMERCIALE
Scopri come la nostra scienza e le nostre innovazioni fanno la differenza nell'accrescere la comprensione della malattia e nell'identificare e trattare il giusto paziente
STAND MEDICA
STAND MEDICA
Scopri come la nostra ricerca innovativa è utilizzata per migliorare la comprensione della patologia e per sviluppare la nostra nuova pipeline
HIGHLIGHT GIORNALIERI
HIGHLIGHT GIORNALIERI
Ogni giorno, registreremo gli eventi e li pubblicheremo sul nostro sito. Riguarda cosa è successo durante il giorno all'ERS o cattura gli highlight di giornata.
Nucala è un marchio registrato GlaxoSmithKline
© 2019 Società del gruppo GSK o licenziante. Marchio di proprietà di società del gruppo GSK o licenziante.
▼ Medicinale sottoposto a monitoraggio addizionale. Ciò permetterà la rapida identificazione di nuove informazioni sulla sicurezza. Agli operatori sanitari è richiesto di segnalare qualsiasi reazione avversa sospetta tramite il sito web dell’Agenzia Italiana del Farmaco: https://www.aifa.gov.it/web/guest/content/segnalazioni-reazioni-avverse.
PM-IT-RS-WCNT-190005: Agosto 2019
Ci dispiace, ma l'utilizzo di questo sito non è supportato su Android 4.3 e versioni inferiori.
Per favore, aggiorni il suo sistema operativo o utilizzi un altro device.